A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT

ABSTRACT: Primary objectives: To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of patients with metastatic colorectal cancer. Primary endpoints: Progression-free survival (PFS)

DISEASE(S): Metastatic Colorectal Cancer,First-line Treatment Of Patients With Metastatic Colorectal Cancer.

PROVIDER: 2521530 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR